Psyadon Pharmaceuticals Overview
- Year Founded
-
2004
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Psyadon Pharmaceuticals General Information
Description
Developer of medicinal drugs intended to be used for treating psychiatric and neurodegenerative diseases. The company's medicinal drugs are focused on discovering, developing and marketing drugs, Ecopipam which selectively blocks the actions of the neurotransmitter dopamine at the D1 subtype in the brain, enabling targeted patients to help them get a cure who previously have no other therapeutic options.
Contact Information
Website
www.psyadonrx.comCorporate Office
- 20451 Seneca Meadows Parkway
- Germantown, MD 20876
- United States
Corporate Office
- 20451 Seneca Meadows Parkway
- Germantown, MD 20876
- United States
Psyadon Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 14-Aug-2018 | Completed | Clinical Trials - Phase 2 | |||
| 4. Debt - General | 18-Feb-2015 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC (Series A1) | 12-Nov-2008 | Completed | Startup | |||
| 2. Accelerator/Incubator | 21-Feb-2005 | $5.2M | Completed | Startup | ||
| 1. Early Stage VC (Series A) | 26-Jul-2004 | $5.2M | $5.2M | Completed | Startup |
Psyadon Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A1 |
Psyadon Pharmaceuticals Patents
Psyadon Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2015058053-A1 | Fused benzazepines for treatment of stuttering | Inactive | 18-Oct-2013 | ||
| AU-2013289922-A1 | Fused benzazepines for treatment of tourette's syndrome | Active | 12-Jul-2012 | ||
| AU-2013289922-B2 | Fused benzazepines for treatment of tourette's syndrome | Active | 12-Jul-2012 | ||
| WO-2014012034-A1 | Fused benzazepines for treatment of tourette's syndrome | Inactive | 12-Jul-2012 | ||
| WO-2014012063-A1 | Pharmaceutical dosage forms comprising ecopipam free base or pharmaceutically acceptable salts thereof | Inactive | 12-Jul-2012 | A61K9/5084 |
Psyadon Pharmaceuticals Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aberdare Ventures | Venture Capital | Minority | ||
| Domain Associates | Venture Capital | Minority | ||
| Maryland Industrial Partnerships | University | |||
| New Enterprise Associates | Venture Capital | Minority |
Psyadon Pharmaceuticals FAQs
-
When was Psyadon Pharmaceuticals founded?
Psyadon Pharmaceuticals was founded in 2004.
-
Where is Psyadon Pharmaceuticals headquartered?
Psyadon Pharmaceuticals is headquartered in Germantown, MD.
-
What industry is Psyadon Pharmaceuticals in?
Psyadon Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Psyadon Pharmaceuticals a private or public company?
Psyadon Pharmaceuticals is a Private company.
-
What is Psyadon Pharmaceuticals’s current revenue?
The current revenue for Psyadon Pharmaceuticals is .
-
How much funding has Psyadon Pharmaceuticals raised over time?
Psyadon Pharmaceuticals has raised $13.2M.
-
Who are Psyadon Pharmaceuticals’s investors?
Aberdare Ventures, Domain Associates, Maryland Industrial Partnerships, and New Enterprise Associates have invested in Psyadon Pharmaceuticals.
-
When was Psyadon Pharmaceuticals acquired?
Psyadon Pharmaceuticals was acquired on 14-Aug-2018.
-
Who acquired Psyadon Pharmaceuticals?
Psyadon Pharmaceuticals was acquired by Emalex Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process